Archit Organosys Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 10, 2025, 11:12 pm

Competitors of Archit Organosys Ltd

All Competitor Stocks of Archit Organosys Ltd

Quarterly Result

Last Updated: August 19, 2025, 11:30 pm

Below is a detailed analysis of the quarterly data for Archit Organosys Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 33.20 Cr.. The value appears to be declining and may need further review. It has decreased from 43.18 Cr. (Mar 2025) to 33.20 Cr., marking a decrease of 9.98 Cr..
• For Expenses, as of Jun 2025, the value is 29.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.76 Cr. (Mar 2025) to 29.06 Cr., marking a decrease of 9.70 Cr..
• For Operating Profit, as of Jun 2025, the value is 4.14 Cr.. The value appears to be declining and may need further review. It has decreased from 4.42 Cr. (Mar 2025) to 4.14 Cr., marking a decrease of 0.28 Cr..
• For OPM %, as of Jun 2025, the value is 12.47%. The value appears strong and on an upward trend. It has increased from 10.24% (Mar 2025) to 12.47%, marking an increase of 2.23%.
• For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 0.06 Cr..
• For Interest, as of Jun 2025, the value is 0.60 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.71 Cr. (Mar 2025) to 0.60 Cr., marking a decrease of 0.11 Cr..
• For Depreciation, as of Jun 2025, the value is 1.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.46 Cr. (Mar 2025) to 1.49 Cr., marking an increase of 0.03 Cr..
• For Profit before tax, as of Jun 2025, the value is 3.05 Cr.. The value appears to be declining and may need further review. It has decreased from 3.31 Cr. (Mar 2025) to 3.05 Cr., marking a decrease of 0.26 Cr..
• For Tax %, as of Jun 2025, the value is 33.11%. The value appears to be improving (decreasing) as expected. It has decreased from 38.67% (Mar 2025) to 33.11%, marking a decrease of 5.56%.
• For Net Profit, as of Jun 2025, the value is 2.04 Cr.. The value appears strong and on an upward trend. It has increased from 2.02 Cr. (Mar 2025) to 2.04 Cr., marking an increase of 0.02 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.99. The value appears strong and on an upward trend. It has increased from 0.98 (Mar 2025) to 0.99, marking an increase of 0.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:55 pm

Growth

Last Updated: September 5, 2025, 2:21 pm

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Archit Organosys Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has increased from 1.63 (Mar 24) to 2.46, marking an increase of 0.83.
• For Diluted EPS (Rs.), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has increased from 1.63 (Mar 24) to 2.46, marking an increase of 0.83.
• For Cash EPS (Rs.), as of Mar 25, the value is 5.36. This value is within the healthy range. It has increased from 4.38 (Mar 24) to 5.36, marking an increase of 0.98.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.72. It has increased from 31.26 (Mar 24) to 33.72, marking an increase of 2.46.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.72. It has increased from 31.26 (Mar 24) to 33.72, marking an increase of 2.46.
• For Dividend / Share (Rs.), as of Mar 25, the value is 0.50. This value is below the healthy minimum of 1. It has increased from 0.00 (Mar 24) to 0.50, marking an increase of 0.50.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.21. It has increased from 55.16 (Mar 24) to 61.21, marking an increase of 6.05.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 4.51 (Mar 24) to 7.83, marking an increase of 3.32.
• For PBIT / Share (Rs.), as of Mar 25, the value is 4.93. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 4.93, marking an increase of 3.18.
• For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has increased from 2.14 (Mar 24) to 3.67, marking an increase of 1.53.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 2.46, marking an increase of 0.83.
• For PBDIT Margin (%), as of Mar 25, the value is 12.78. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 12.78, marking an increase of 4.61.
• For PBIT Margin (%), as of Mar 25, the value is 8.05. This value is below the healthy minimum of 10. It has increased from 3.17 (Mar 24) to 8.05, marking an increase of 4.88.
• For PBT Margin (%), as of Mar 25, the value is 6.00. This value is below the healthy minimum of 10. It has increased from 3.87 (Mar 24) to 6.00, marking an increase of 2.13.
• For Net Profit Margin (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 5. It has increased from 2.94 (Mar 24) to 4.02, marking an increase of 1.08.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.29. This value is below the healthy minimum of 15. It has increased from 5.20 (Mar 24) to 7.29, marking an increase of 2.09.
• For Return on Capital Employeed (%), as of Mar 25, the value is 13.10. This value is within the healthy range. It has increased from 4.85 (Mar 24) to 13.10, marking an increase of 8.25.
• For Return On Assets (%), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 5. It has increased from 3.08 (Mar 24) to 4.10, marking an increase of 1.02.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.06, marking a decrease of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.38, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.09. It has increased from 0.98 (Mar 24) to 1.09, marking an increase of 0.11.
• For Current Ratio (X), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.35, marking an increase of 0.14.
• For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.11 (Mar 24) to 1.25, marking an increase of 0.14.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 32.43. This value exceeds the healthy maximum of 8. It has increased from 10.10 (Mar 24) to 32.43, marking an increase of 22.33.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 30.73 (Mar 24) to 0.00, marking a decrease of 30.73.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.40 (Mar 24) to 0.00, marking a decrease of 11.40.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 69.27 (Mar 24) to 0.00, marking a decrease of 69.27.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.60 (Mar 24) to 0.00, marking a decrease of 88.60.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.23. This value is within the healthy range. It has increased from 3.59 (Mar 24) to 6.23, marking an increase of 2.64.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.96. This value is below the healthy minimum of 3. It has increased from 0.98 (Mar 24) to 2.96, marking an increase of 1.98.
• For Enterprise Value (Cr.), as of Mar 25, the value is 103.28. It has decreased from 110.21 (Mar 24) to 103.28, marking a decrease of 6.93.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.97 (Mar 24) to 0.82, marking a decrease of 0.15.
• For EV / EBITDA (X), as of Mar 25, the value is 6.43. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 6.43, marking a decrease of 5.48.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.61, marking a decrease of 0.17.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 69.26 (Mar 24) to 0.00, marking a decrease of 69.26.
• For Price / BV (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.38 (Mar 24) to 1.11, marking a decrease of 0.27.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.61, marking a decrease of 0.17.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness